$675 million for MRSA antibiotic.
D004345:Drug Industry / Q000191:economics*; D006801:Humans; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects; D013207:Staphylococcal Skin Infections / Q000188:drug therapy* / Q000382:microbiology; D017334:Teicoplanin / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use
D017334:Teicoplanin; C469289:dalbavancin